Combination of | |
---|---|
Emtricitabine | Nucleoside analog reverse-transcriptase inhibitor |
Rilpivirine | Non-nucleoside reverse transcriptase inhibitor |
Tenofovir disoproxil | Nucleotide analog reverse-transcriptase inhibitor |
Clinical data | |
Trade names | Complera, Eviplera |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG | |
(verify) |
Emtricitabine/rilpivirine/tenofovir (trade names Complera, Eviplera) is a fixed-dose combination of antiretroviral drugs for the treatment of HIV/AIDS. [1] The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the Food and Drug Administration in August 2011, and by the European Medicines Agency in November 2011, [2] for patients who have not previously been treated for HIV. [3] It is available as a once-a-day single tablet.
In the European Union it is marketed as Eviplera and in the US as Complera. [4]
Emtricitabine/rilpivirine/tenofovir is indicated for treatment of HIV-1 in adults naïve to HIV-1 medications (where the virus has not developed resistance to these anti-HIV medications) and who have no more than 100,000 copies per mL of HIV-1 RNA in their blood (“ viral load”). [5] [6]
Contraindications
Use of emtricitabine/rilpivirine/tenofovir with the following medicines is contraindicated, as they lead to reduced blood levels of rilpivirine and in turn reduce the effectiveness of emtricitabine/rilpivirine/tenofovir: [5] [8]
Combination of | |
---|---|
Emtricitabine | Nucleoside analog reverse-transcriptase inhibitor |
Rilpivirine | Non-nucleoside reverse transcriptase inhibitor |
Tenofovir disoproxil | Nucleotide analog reverse-transcriptase inhibitor |
Clinical data | |
Trade names | Complera, Eviplera |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG | |
(verify) |
Emtricitabine/rilpivirine/tenofovir (trade names Complera, Eviplera) is a fixed-dose combination of antiretroviral drugs for the treatment of HIV/AIDS. [1] The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the Food and Drug Administration in August 2011, and by the European Medicines Agency in November 2011, [2] for patients who have not previously been treated for HIV. [3] It is available as a once-a-day single tablet.
In the European Union it is marketed as Eviplera and in the US as Complera. [4]
Emtricitabine/rilpivirine/tenofovir is indicated for treatment of HIV-1 in adults naïve to HIV-1 medications (where the virus has not developed resistance to these anti-HIV medications) and who have no more than 100,000 copies per mL of HIV-1 RNA in their blood (“ viral load”). [5] [6]
Contraindications
Use of emtricitabine/rilpivirine/tenofovir with the following medicines is contraindicated, as they lead to reduced blood levels of rilpivirine and in turn reduce the effectiveness of emtricitabine/rilpivirine/tenofovir: [5] [8]